APTOCROM Inc.
Financials
Valuation Metrics
APTOCROM Inc.'s Market Cap is ₩262B. At end of 2025 it was ₩729B. Ranked #2112 of 2,405 in KR market (top 88%), #1360 of 1,627 on KOSDAQ (top 84%), #217 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 94%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 26.19B KRW | KR#2,112/2,405 Sec#217/231 |
| Revenue | 10.78B KRW | KR#2,269/2,405 Sec#174/231 |
| Net Income | 38.26B KRW | KR#499/2,405 Sec#31/231 |
| Total Assets | 379.47B KRW | KR#902/2,405 Sec#53/231 |
| Net Assets | 361.63B KRW | KR#642/2,405 Sec#41/231 |
| Employees | 15 | KR#2,259/2,405 Sec#214/231 |
| Value | ||
| P/E | 0.68x | KR#7/2,405 Sec#1/231 |
| P/B | 0.07x | KR#11/2,405 Sec#1/231 |
| P/S | 2.43x | KR#1,929/2,405 Sec#114/231 |
| FCF Yield | 9.25% | KR#667/2,405 Sec#29/231 |
| Profitability | ||
| ROE | 10.58% | KR#568/2,405 Sec#39/231 |
| ROA | 10.08% | KR#270/2,405 Sec#20/231 |
| Op. Margin | -12.77% | KR#2,026/2,405 Sec#136/231 |
| Revenue Growth | -16.59% | KR#2,064/2,405 Sec#189/231 |
| Financial Health | ||
| Debt Ratio | 4.93% | KR#34/2,405 Sec#10/231 |
| Total Debt | 8.54B KRW | KR#1,665/2,405 Sec#153/231 |
| FCF | 2.42B KRW | KR#1,052/2,405 Sec#73/231 |
| Cash | 4.09B KRW | KR#2,071/2,405 Sec#193/231 |
| Current Ratio | 5.63x | KR#238/2,405 Sec#45/231 |
| Performance | ||
| 1Y Return | -67.58% | KR#2,247/2,405 Sec#214/231 |
| 1M Return | -7.28% | KR#918/2,405 Sec#85/231 |
| From 52W High | -72.46% | KR#2,129/2,405 Sec#185/231 |
| 1Y MDD | -72.97% | KR#2,080/2,405 Sec#182/231 |
| Trading | ||
| Volume | 2,044 shares | KR#2,266/2,405 Sec#227/231 |
| Trading Value | 3.5M KRW | KR#2,335/2,405 Sec#231/231 |
| Foreign Own. | 0.00% | KR—/2,405 Sec—/231 |
| Per Share | ||
| EPS | 2,529 KRW | KR#391/2,405 Sec#26/231 |
| BPS | 23,898 KRW | KR#468/2,405 Sec#32/231 |
Company Info
This company, established in 1988 and listed on KOSDAQ in 2009, operates pharmaceutical distribution and real estate/equipment leasing, holding three unlisted subsidiaries. Its subsidiary Aprogen I&C specializes in special nuclear power plant insulation and foamed glass insulation materials. The company responds to increasing well-being demand from an aging population and anticipates rising foamed glass insulation material demand from nuclear power plant exports and a shipbuilding boom, enhancing its business competitiveness. Aptokrom was established in 1998 and is headquartered in Seongnam-si, Gyeonggi-do.